TERN
$48.44-0.62 (-1.26%)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that i...
Recent News
How Vestal Point’s Big Bet On TERN-701 At Terns Pharmaceuticals (TERN) Has Changed Its Investment Story
Vestal Point Capital recently disclosed a major investment in Terns Pharmaceuticals, acquiring 4,500,000 shares valued at US$181.80 million to back the company’s clinical-stage pipeline in liver, metabolic and oncology indications. This institutional vote of confidence arrives as Terns advances TERN-701 toward pivotal trials for chronic myeloid leukemia, supported by earlier encouraging clinical data and a reinforced cash position. We’ll now examine how Vestal Point Capital’s large stake and...
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
This clinical-stage biotech develops therapies for CML, NASH, and obesity.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.